TNDM: Tandem Diabetes Care, Inc. - Summary | Jitta

Tandem Diabetes Care, Inc.

NASDAQ:TNDM

Price
$21.22
Loss Chance
53.8%
2.65JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
617 / 1,142
3,822 / 5,003
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (36)
Recent Business Performance (0)
Financial Strength (51)
Return to Shareholders (10)
Competitive Advantage (43)
Jitta Signs
SG&A to SalesDecreasing
Revenue and EarningEarning loss detected in 2018
Operating MarginDeclined
Debt LevelHigh Long Term Debt
Recent Business PerformanceEarning decline 474.09% in the last quarter (yoy)
Key Stats
Jitta Score
Jitta Line
2.65
100.00%
2.03
336.26%
Health Care Equipment
6.23
22.23%
4.76
21.25%
6.29
15.60%
COMPANY DESCRIPTION
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company’s flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump’s software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.